Trellus (TRLS ) CEO, Monique Fayad and Co-Founder Marla Dubinsky, explain how their resilience driven, connected health system addresses both clinical needs and behaviour targeting those suffering with chronic illness and how the system leads to positive health outcomes and cost savings for the health system and insurers.
The Company is currently focussing on inflammatory bowel disease (IBD) but Monique explains it plans to scale to other chronic diseases starting with the 7 that are under license with Mount Sinai Hospital.
She also outlines the business model and the plan to receive additional revenue from data going forward.
The team state that as the system is a methodology no FDA clearance is required which should lead to patients under management this year